Occam Recruits CSO for Public Gene Therapy Company, Adverum
In February 2024, Occam recruited Romuald “Romu” Corbau, PhD as Chief Scientific Officer for Adverum Biotechnologies (Nasdaq: ADVM).
Corbau has over 25 years of life science experience, ranging from startups to global pharmaceutical companies in the United States and Europe. He joins Adverum from GenEdit, where he served as Chief Scientific Officer. Prior to joining GenEdit, Corbau progressed from Vice President of Research to Chief Scientific Officer at Freeline. Before GenEdit, Corbau was the Translational Lead at Spark Therapeutics and held various research positions at Pfizer, CISTIM in Belgium, and Children’s Hospital of Philadelphia.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.